Growing Research Finds Psychedelics Effective in Treating Disease
August 22, 2016
(The Baltimore Sun) – McGlothlin was part of a group study on the effects of psilocybin, the active hallucinogenic ingredient in “magic mushrooms,” on smoking cessation. The study represents a resurgence in research at Johns Hopkins, New York University and other academic institutions looking at whether mind-altering psychedelics, such as LSD, mushrooms and ecstasy can be effective in treating a variety of emotional and addictive disorders. Scientists have discovered that psychedelic drugs have the potential to relieve clinical depression, anxiety in cancer patients, depression in hospice patients, post-traumatic stress disorder and obsessive-compulsive disorder.